Replimune Group, Inc (REPL)

Etorro trading 970x250
Replimune Group, Inc (REPL) Logo

About Replimune Group, Inc

Replimune Group, Inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company’s lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts. Address: 500 Unicorn Park, Woburn, MA, United States, 01801

Replimune Group, Inc News and around…

Latest news about Replimune Group, Inc (REPL) common stock and company :

Replimune Group: Q4 Earnings Insights
19 May, 2022 FinancialContent

Replimune Group (NASDAQ:REPL) reported its Q4 earnings results on Thursday, May 19, 2022 at 08:00 AM. Here's what investors need to ...

Replimune Reports Fiscal Fourth Quarter and Year-Ended 2022 Financial Results and Provides Corporate Update
19 May, 2022 Yahoo! Finance

Enrollment in the CERPASS clinical trial with RP1 in cutaneous squamous cell carcinoma (CSCC) expected to be completed in mid-year 2022; top line data expected Q1 2023 Directional data from the first 75 patents with 6 months follow up from the IGNYTE clinical trial with RP1 in anti-PD1 failed melanoma expected in late 2022 Phase 2 development plan for RP2/RP3 in HCC, CRC and SCCHN announced WOBURN, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage bio

XBI's Holdings Imply 141% Gain Potential
19 May, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the ETF (XBI), we found that the implied analyst target price for the ETF based upon its underlying holdings is $163.44 per unit.

10 Best Stocks to Buy Under $20 According to Jeremy Green’s Redmile Group
03 May, 2022 Yahoo! Finance

In this piece, we will take a look at the ten best stocks to buy under $20 according to Jeremy Green’s Redmile Group. If you want to skip the details about the hedge fund, then take a look at the 5 Best Stocks to Buy Under $20 According to Jeremy Green’s Redmile Group. Jeremy Green […]

We Think Replimune Group (NASDAQ:REPL) Can Afford To Drive Business Growth
14 Apr, 2022 Yahoo! Finance

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Peek Under The Hood: PRFZ Has 32% Upside
07 Apr, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco FTSE RAFI US 1500 Small-Mid ETF (PRFZ), we found that the implied analyst target price for the ETF based upon its underlying holdings is $234.60 per unit.

The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict
30 Mar, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus J&J, ViiV Co-developed ...

Replimune Provides New Clinical Data, Broad Program Update and Future Development Strategy for its Tumor-Directed Oncolytic Immunotherapies
30 Mar, 2022 Yahoo! Finance

RP1 combined with Opdivo® (nivolumab) continues to demonstrate deep and durable responses in patients with melanoma and non-melanoma skin cancers (NMSC); new positive initial data in patients with anti-PD1 failed NMSC Initial data shows clinical activity with RP1 monotherapy in solid organ transplant recipients with cutaneous squamous cell carcinoma (CSCC) Broad Phase 2 development planned for RP2/RP3 in hard-to-treat tumor types Virtual investor event to be held today at 8:00 am ET WOBURN, Mass

The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
27 Mar, 2022 FinancialContent

Biotech stocks reversed course in the week endingMarch 25, as an increase in risk appetite prompted traders to move money out of ...

Replimune to Host Virtual Investor Event on March 30, 2022
21 Mar, 2022 Yahoo! Finance

Event to begin at 8:00 AM ETWOBURN, Mass., March 21, 2022 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that members of its executive team and Key Opinion Leaders will host an investor event to present updated data from the completed cohorts of the Phase 2 IGNYTE clinical trial in non-melanoma skin cancer (“NMSC”) and melanoma. Additionally, t

Peek Under The Hood: LABU Has 110% Upside
03 Mar, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Daily S&P Biotech Bull 3X Shares ETF (LABU), we found that the implied analyst target price for the ETF based upon its underlying holdings is $34.22 per unit.

Stocks That Hit 52-Week Lows On Friday
18 Feb, 2022 FinancialContent

On Friday, 313 companies hit new 52-week lows. Things to Consider About Today's 52-Week Lows: The ...

Replimune to Present at the 11th Annual SVB Leerink Global Healthcare Conference
11 Feb, 2022 Yahoo! Finance

WOBURN, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference being held virtually on Friday, February 18, 2022 at 8:40 AM ET. A simultaneous webcast will be available in the

Replimune Group: Q3 Earnings Insights
03 Feb, 2022 FinancialContent

Replimune Group (NASDAQ:REPL) reported its Q3 earnings results on Thursday, February 3, 2022 at 08:00 AM. Also check out ...

Replimune Reports Third Fiscal Quarter Financial Results and Provides Corporate Update
03 Feb, 2022 Yahoo! Finance

Data expected to be presented at an investor event in March 2022: Data updates from the completed RP1 IGNYTE cohorts in anti-PD1 naïve non-melanoma skin cancer (NMSC) and anti-PD1 naïve and failed melanoma Initial data from the ongoing study in anti-PD1 failed NMSC and from the ARTACUS trial, a Phase 1b/2 trial of RP1 as monotherapy in solid organ transplant recipients with cutaneous squamous cell carcinoma (CSCC) RP3 initial data and the Phase 2 development plan for RP2/3 WOBURN, Mass., Feb. 03

Commit To Purchase Replimune Group At $12.50, Earn 11% Annualized Using Options
01 Feb, 2022 FinancialContent

Investors eyeing a purchase of Replimune Group Inc (REPL) shares, but cautious about paying the going market price of $19.49/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the August put at the $12.50 strike, which has a bid at the time of this writing of 75 cents..

The Daily Biotech Pulse: ImmunityBio Reports Positive Readout, Valneva Starts Late-Stage Chikungunya Vaccine Study, Sio Gene Shelves Parkinson's Program
01 Feb, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus ImmunityBio Announces ...

Replimune Announces the Departure of Dr. Otello Stampacchia from its Board of Directors
31 Jan, 2022 Yahoo! Finance

WOBURN, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced Otello Stampacchia, Ph.D., of Omega Funds, has resigned from the company’s Board of Directors. Dr. Stampacchia joined the Replimune Board in 2015, concurrent with Omega co-leading Replimune’s seed financing. Dr. Stampacchia has resigned to focus his efforts on his growi

Stocks That Hit 52-Week Lows On Thursday
20 Jan, 2022 FinancialContent

During Thursday's morning trading, 152 companies set new 52-week lows. Noteworthy Points From Today's 52-Week ...

Replimune Provides 2021 Year End Review and Overview of Expected 2022 Milestones
10 Jan, 2022 Yahoo! Finance

CERPASS clinical trial with RP1 in CSCC on track to complete enrollment mid-year with the primary analysis trigger six months thereafter IGNYTE anti-PD1 failed melanoma, evaluating RP1 in combination with Opdivo® on track to release interim data in late 2022 Phase 2 development plan for RP2/3 to be presented in the first quarter of 2022 Replimune to provide corporate update at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022 WOBURN, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- R

Replimune to Present at the 40th Annual J.P. Morgan Healthcare Conference
04 Jan, 2022 Yahoo! Finance

WOBURN, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present at the 40th Annual J.P. Morgan Healthcare Conference being held virtually on Monday, January 10, 2022 at 7:30 AM ET. A simultaneous webcast will be available in the Investors section of Repli

XBI's Underlying Holdings Imply 82% Gain Potential
22 Dec, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR— S&P— Biotech ETF (XBI), we found that the implied analyst target price for the ETF based upon its underlying holdings is $212.07 per unit.

Is Replimune Group, Inc. (NASDAQ:REPL) Expensive For A Reason? A Look At Its Intrinsic Value
17 Dec, 2021 Yahoo! Finance

How far off is Replimune Group, Inc. ( NASDAQ:REPL ) from its intrinsic value? Using the most recent financial data...

Tekla Life Sciences Investors Buys Amgen Inc, Alkermes PLC, Novavax Inc, Sells Moderna Inc, ...
09 Dec, 2021 Yahoo! Finance

Investment company Tekla Life Sciences Investors (Current Portfolio) buys Amgen Inc, Alkermes PLC, Novavax Inc, Intra-Cellular Therapies Inc, AstraZeneca PLC, sells Moderna Inc, Allakos Inc, Blueprint Medicines Corp, Ascendis Pharma A/S, BridgeBio Pharma Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Tekla Life Sciences Investors.

Replimune Appoints Christy Oliger to its Board of Directors
02 Dec, 2021 Yahoo! Finance

WOBURN, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing a range of product candidates derived from its oncolytic immuno-gene therapy platform, today announced the appointment of Christy Oliger to the Company’s Board of Directors effective December 1, 2021. “We are delighted to welcome Christy to Replimune’s Board of Directors,” said Philip Astley-Sparke, Chief Executive Officer of Replimune. “Christy brings nearly 30 years of comm

Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021
19 Nov, 2021 FinancialContent

Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE:EQT) from Equal-Weight to Overweight. For the ...

Replimune Provides Updated Data from RP2 at the 2021 Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting
12 Nov, 2021 Yahoo! Finance

RP2 data demonstrates deep and durable responses in difficult to treat cancers both as monotherapy and in combination with Opdivo® (nivolumab) Initiated Phase 1 expansion of RP2 in combination with Opdivo focused on patients with liver metastases WOBURN, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced updated interim data from the Phase 1 data fr

The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
08 Nov, 2021 FinancialContent

Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good ...

Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update
04 Nov, 2021 Yahoo! Finance

RP1; Full patient accrual in CERPASS registration-directed clinical trial continues to be expected in mid-year 2022 with the primary data trigger expected in late 2022. Interim data in the IGNYTE anti-PD1 failed registration directed melanoma cohort continues to be expected in late 2022 RP2; Updated monotherapy and combination data with Opdivo (nivolumab) to be presented at SITC this month; Phase 1 protocol amendment expansion to add additional patients with liver metastases filed RP2/3; Detaile

Replimune to Present at Two Upcoming Investor Conferences
01 Nov, 2021 Yahoo! Finance

WOBURN, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today announced that members from the Replimune management team will present and host investor meetings at the following two conferences: BMO Biopharma Spotlight Series: Emerging Trends & Therapeutics in OncologyPanel: Pioneering the Next Generation of Oncolytic Virus TherapeuticsDate: Monday, November 8, 2

Replimune Group, Inc (REPL) is a NASDAQ Common Stock listed in , ,

970x250